BOULDER, Colo., March 10, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and Scientific ...
Dyne Therapeutics reports positive long-term data for DYNE-251 in Duchenne muscular dystrophy, aiming for U.S. accelerated approval in 2026. Dyne Therapeutics announced new long-term clinical data ...
SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR) (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of ...
RegenXBio Inc. ((RGNX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...
TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (MSCL:CA) (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to ...
SAN FRANCISCO -- Givinostat (Duvyzat) had a manageable long-term safety profile in Duchenne muscular dystrophy, data from an open-label extension study suggested. Most treatment-emergent adverse ...
6 Health and Social Research Center, Universidad de Castilla La-Mancha, Cuenca, Spain Objective To examine the predictive validity of field-based muscular strength tests in relation to incident ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results